Trial reportBMC cancer2026
Impact of concurrent chemotherapy dose on long-term survival in locally advanced nasopharyngeal carcinoma: a 10-year single-center study.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study is to compare the acute adverse reactions and long-term efficacy of concurrent chemoradiotherapy with different doses of cisplatin in the treatment of nasopharyngeal carcinoma.
methodsOne hundred forty patients with locally advanced nasopharyngeal carcinoma treated at a hospital in Guangxi, China from March to October 2010 were randomly assigned to the A group (n = 72) (80 mg/m ²) and a B group (n = 68) (100 mg/m ²) according to different cisplatin usage regimens. The acute toxicities and long-term survival of the two groups were compared and analyzed.
resultsThe median follow-up time of this study was 125 months (5 -183 months), and the overall survival (OS), local recurrence-free survival (LRRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) of the two groups were not statistically significant. The 10-year OS, LRRFS, PFS, and DMFS were 64.6%, 88.1%, 83.4%, and 97.7% in the B group and 66.5%, 90.8%, 84.5%, and 96.2% in the A group. Multivariate analysis showed that age and T stage were independent risk factors for DMFS. In term of acute toxicities, the control group had an increased risk of bone marrow suppression and renal dysfunction.
conclusionThis study shows that reducing the dose of cisplatin concomitant chemotherapy does not reduce the long-term survival benefit of patients with locally advanced nasopharyngeal carcinoma, and it is beneficial to reduce the risk of acute toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.